|08/07/17||Coherus BioSciences Reports Second Quarter 2017 Corporate Highlights and Financial Results|
|REDWOOD CITY, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reviewed corporate events and reported financial results for the quarter ended June 30, 2017.
Corporate Highlights for the Second Quarter 2017 Include:
Oncology therapeutic franchise:
CHS-1701 (pegfilgrastim (Neulasta®) biosimilar candidate)
• Announced completion of initial phases of the Biologic Price Competition and Innovation Act patent exchange with Amgen.
• Announced receip... |
|08/07/17||Coherus BioSciences Files Petition for Inter Partes Review of ENBREL® Patent 8,163,522|
|REDWOOD CITY, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that it has filed a petition for Inter Partes Review (“IPR”) in the United States Patent and Trademark Office seeking invalidation of U.S. Patent 8,163,522 (“ ‘522 patent”). The ‘522 patent, controlled by Amgen, is generally directed to a method for making etanercept, the pharmaceutically active component of ENBREL®. Coherus also announced its intention to file an IPR in the near fu... |
|07/24/17||Coherus BioSciences to Report Second Quarter 2017 Financial Results on August 7th|
|REDWOOD CITY, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its second quarter 2017 financial results will be released after market close on Monday, August 7, 2017. Starting at 4:30 p.m. EDT, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.
After releasing second quarter 2017 financial results, we will post them on the Coherus BioSciences website at http://inve... |
|06/12/17||Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)|
|Management to host a call today at 8:00 a.m. EDT to discuss FDA feedback
REDWOOD CITY, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for its biologics license application (“BLA”) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate, under the 351(k) pathway.
The CRL primarily focused on the FDA request for a reanalysis of a subset of ... |